Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization

• Main Authors: Hongjie Mu (Author), Yiyun Wang (Author), Yongchao Chu (Author), Ying Jiang (Author), Hongchen Hua (Author), Liuxiang Chu (Author), Kaili Wang (Author), Aiping Wang (Author), Wanhui Liu (Author), Youxin Li (Author), Fenghua Fu (Author), Kaoxiang Sun (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Bevacizumab is an anti-vascular endothelial growth factor drug that can be used to treat choroidal neovascularization (CNV). Bevacizumab-loaded multivesicular liposomes (Bev-MVLs) have been designed and developed to increase the intravitreal retention time of bevacizumab and reduce the number of inj...